Compared to 2011 in 2012 the purchase of drugs for treatments like hematopoietic and related tissues, hemophilia, multiple sclerosis, as well as post-transplant organs and other tissues, will increase by 13%.
•The budget allocation for these purposes in 2012 – 2014 will amount up to 54.17 billion Rubles yearly.
Chameleon Pharma Consulting comments: The Russian government tries to step by step implement better programs to support reimbursement and people’s health. Companies, who like to enter the Russian market or to grow their Russian sales base, need to make a clear decision in 2011/2012. The government tries to support the local Pharma industry or those international players with own production in Russia. It might not be feasible or clever to invest into production for medium sized Pharma players. Virtual production models and partner models can be implemented to solve the issue for medium sized Pharma players.
Weitere Informationen unter:
http://www.chameleon-pharma.com